For patients with cancer and brain metastases (BM) and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 ...

The use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with reduced risks for developing substance use disorders (SUDs).

Treatment with GLP-1 RAs for T2D and obesity is associated with increased risk for osteoporosis, gout, and osteomalacia compared with nonuse.

Among patients eligible for metabolic and bariatric surgery (MBS), glucagon-like peptide-1 receptor agonist (GLP-1 RA) ...

Retrospective cohorts show GLP-1 RA exposure yields ~5% relative weight reduction and an apparent OS advantage, while ...

Twenty point six percent of patients followed a switcher trajectory within 12 months, with higher persistence seen for switchers.

The findings of this cohort study suggest that glucagon-like peptide–1 receptor agonist (GLP-1 RA) use was associated with significant reduction in all-cause mortality among patients with cancer with ...

Among youth aged 12 to 17 years with BMI in at least the 95th percentile for age and sex, 20% had 1 or more GLP-1 RA prescriptions.

GLP-1 receptor agonist use was linked to a significantly higher risk for osteoporosis, gout, and osteomalacia over 5 years.

What should oncology nurses and advanced practice providers understand about GLP-1 RAs in the care of patients with breast ...

BMJ cohort study links GLP-1 drugs such as semaglutide to lower substance use disorder risk and reduced addiction-related complications in adults with diabetes.